Intercept To Discontinue All NASH-related Investment And Reduce Workforce By Approximately One Third; R&D Investment Prioritized On Fixed-dose Combination Of OCA And Bezafibrate And It Anticipates Achieving Profitability In 2024
Portfolio Pulse from Benzinga Newsdesk
Intercept Pharmaceuticals plans to discontinue all NASH-related investments and reduce its workforce by one third. The company will prioritize R&D investment on a fixed-dose combination of OCA and Bezafibrate, aiming for profitability in 2024.
June 23, 2023 | 10:39 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intercept Pharmaceuticals' decision to discontinue NASH investments and reduce workforce may lead to short-term uncertainty, but the focus on OCA and Bezafibrate could drive long-term growth.
Intercept's decision to discontinue NASH investments and reduce its workforce may cause short-term uncertainty for investors. However, the company's focus on the fixed-dose combination of OCA and Bezafibrate could lead to long-term growth and profitability by 2024.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100